Biogen Q4 Earnings Review: Why I'm Calling Time On This 'Powder Puff' Pharma
Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...
Pharmaceutical Technology on MSN6d
Royalty Pharma pays $250m for rights to Biogen’s lupus drug
Royalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus ...
The Pharma Letter1d
Biogen and Stoke Thera ink deal on zorevunersen development
Stoke Therapeutics’ stock climbed 8% early Tuesday, after the company and Biogen today announced a collaboration to develop ...
BioSpace18h
5 Pharma Powerhouses Facing Massive Patent Cliffs—And What They’re Doing About It
Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...
Yahoo Finance6d
Royalty Pharma pays $250m for rights to Biogen’s lupus drug
Royalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus medication litifilimab. In return, Royalty Pharma will receive undisclosed ...
The Pharma Letter15h
Mona Kotecha named Ventus CMO
Privately-held Ventus Therapeutics, a biopharma with two novel small-molecule programs entering Phase II development for ...
Biogen (BIIB) Gets a Buy from Mizuho Securities
Mizuho Securities analyst Salim Syed maintained a Buy rating on Biogen (BIIB – Research Report) yesterday and set a price target of $207.00.
MM&M5d
Pharma brands are struggling to keep the attention of digitally savvy HCPs
It’s critical to understand what a digitally savvy HCP is in 2025 and what’s impeding pharma's communications with this ...
Barchart on MSN21h
2 Hot Growth Stocks Poised for Gains of Up to 370%, According to Wall Street
Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.